Aethlon Medical (AEMD) Cash & Equivalents (2010 - 2026)

Aethlon Medical's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $5.0 million for Q1 2026.

• Quarterly Cash & Equivalents fell 8.63% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (down 8.63% YoY) and the FY2026 annual result came in at $5.0 million, down 8.63% from the prior year.
• Cash & Equivalents was $5.0 million for Q1 2026 at Aethlon Medical, down from $7.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $19.7 million in Q3 2022 and bottomed at $3.8 million in Q2 2025.
• A 5-year average of $10.0 million and a median of $8.1 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents soared 73.19% — and 2024, when it tumbled 62.18%.
• Aethlon Medical's Cash & Equivalents stood at $17.6 million in 2022, then sank by 54.17% to $8.1 million in 2023, then plunged by 39.04% to $4.9 million in 2024, then surged by 43.6% to $7.1 million in 2025, then declined by 28.75% to $5.0 million in 2026.
• Business Quant data shows AEMD's Cash & Equivalents at $5.0 million in Q1 2026, $7.1 million in Q4 2025, and $6.0 million in Q3 2025.